Skip to content
Screener

SG&A at other companies

Azenta logo
AzentaAZTA
$67.17M+11.8%
Cencora logo
CencoraCOR
$2.13B+27.5%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$1.91B
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$212.4M+1.7%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$228.9M+19.5%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$7.97M

Other financials

Income statement

See full
Revenue$49.0M+7.7%
Gross profit$22.8M+6.8%
Operating income-$10.0M-4.0%
Net income-$8.3M-108%
EPS (diluted)-$0.20-109%

Balance sheet

See full
Cash & equivalents$269.3M+10.6%
Total debt$232.3M+423%
Total equity$490.7M-5.5%
Total assets$756.2M-2.3%

Cash flow

See full
Operating cash flow$1.1M+115%
CapEx$9.1M+109%
Free cash flow-$8.0M+31.8%

Valuation

See full
Market cap$762.08M+87.9%
Enterprise value$725.12M+251%
P/E9.2×
P/S4.1×+1.6×

Profitability

See full
Gross margin47.1%+0.8pp
Operating margin-21.2%-3.2pp
Net margin41.4%+23.4pp
FCF margin-10.7%-3.4pp

Returns & leverage

See full
Return on equity15.3%+9.1pp
Debt / equity0.5×+0.4×
Current ratio2.1×-14.2×

Where this comes from

Reported directly by CryoPort, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: CryoPort, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-092107
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Total cost of revenue26,14724,07752,03246,476
Gross margin22,82421,37744,73740,018
Operating costs and expenses:
Selling, general and administrative28,01126,90855,63148,809
Engineering and development4,8524,1188,7598,052
Total operating costs and expenses32,86331,02664,39056,861
Loss from operations(10,039)(9,649)(19,653)(16,843)
Other income (expense):

Cover / Front Matter

FAQ

What is CryoPort, Inc.'s SG&A?
CryoPort, Inc. (CYRX) reported SG&A of $28.01M in Q2 2026.
How has CryoPort, Inc.'s SG&A changed year-over-year?
CryoPort, Inc.'s SG&A increased by 4.1% year-over-year, from $26.91M to $28.01M.
What is the long-term trend for CryoPort, Inc.'s SG&A?
Over 4 years (2021 to 2025), CryoPort, Inc.'s SG&A has grown at a 1.3% compound annual growth rate (CAGR), from $97.56M to $102.82M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Ask your AI about CryoPort, Inc.'s sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude